Question Bank › The feared thing keeps not happening

The feared thing keeps not happening

The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i

Calls Tested
994
Answered YES
93
Hit Rate
9.4%
rare by design

RLX Technology Inc. (RLX) — this company's answers

NO on the Q1 2022 call 2022-05-20 C
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断是否存在一个具体的负面担忧,以及管理层是否用已观察到的证据反驳。 首先,寻找具体的担忧。在电话会议中,分析师的问题和管理的回答中,有哪些担忧? - 分析师Lydia问及监管许可、零售许可、新产品反馈,以及非排他性零售条款对竞争格局的影响。管理层的回答提到他们已提交制造许可申请,等待批准,并自信成为首批获得许可的制造商。关于零售许可,他们相信大多数零售商能获得。关于新产品,他们正在进行测试。关于竞争,他们表示没有看到竞争格局有太大变化,并认为品牌、NPS等更重要。这里没有明显的“负面结果”担忧,更多是询问进展。 - 分析师Charlie问及第二季度销售受COVID影响,以及分销商和零售商在试点地区的状况。管理层回答第二季度业绩稳健,符合预期,试点地区合作顺利,没有看到分销商流失。这里似乎没有具体的负面担忧,只是询问情况。 - 分析师Peihang问及库存水平,特别是渠道库存和用户囤货,以及成本削减措施。管理层回答库存水平低,渠道库存下降,用户购买量增加,并提到成本优化措施。这里也没有明显的负面担忧。 但注意,在管理层开场发言中,他们提到“e-vapor industry is currently being reshaped by a mix of regulatory developments”,并提到“we remain confident in our strategy”。他们提到监管变化,但似乎没有具体担忧。 再仔细看,是否有分析师或管理层提到“担忧”或“恐惧”?例如,分析师可能担心监管导致市场份额下降,或担心非排他性导致竞争加剧。但管理层在回答Lydia时提到“we do not see that the competitive landscape has changed much recently”,并说“we believe that our market leadership is based on these key backers rather than the exclusivity”。这似乎是对竞争担忧的回应,但这是否是“具体负面结果”?可能分析师担心失去排他性会导致市场份额下降,但管理层用观察到的证据反驳了吗?他们提到“we have sensed some retailers who are previously on mono-brand stores in the industry start selling other brands products”,但随后说“these brands have not significant retail sales”,并说“we can still maintain a relatively high market share”。这里管理层引用了观察到的现象(其他品牌销售不显著),但这是否是“已观察到的证据”?他们提到“based on our observation”,但具体数据没有给出。不过,这算是对担忧的反驳。 但问题要求“SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company”。在电话会议中,是否有这样的担忧被明确表达?分析师的问题更多是询问进展,而不是表达担忧。例如,Lydia问“what could be the initial feedback from your new products”,这更像是询问,而不是担忧。Charlie问“how these COVID control measures could impact your sales”,这是询问影响,但管理层回答“quarter-to-date performance has been robust”,这算是反驳吗?但COVID影响是宏观的,不是公司特定的。 再读管理层开场:“As you are probably aware, the e-vapor industry is currently being reshaped by a mix of regulatory developments and solid demand for high-quality sales products, both of which are influencing our short and medium-term strategy and outlook.” 这里没有明确担忧。 在问答中,管理层提到“we have not seen any significant attrition of our existing distributors”,这可能是对分销商流失担忧的反驳,但分析师没有明确问这个。 或许担忧是“监管导致业务受损”,但管理层在开场说“we fully embraced these new regulations”,并说“this will benefit those existing industry players”,这更像是乐观。 再考虑是否有分析师直接问“你担心什么”?没有。 因此,可能没有明确的“具体负面结果”被命名。分析师的问题都是中性的询问,没有表达担忧。管理层也没有承认有担忧。 但注意,在管理层回答Lydia时,提到“we do not see that the competitive landscape has changed much recently”,这暗示可能有人担心竞争加剧,但管理层用观察反驳。然而,这并没有被分析师

← Back to the full RLX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company — a worry that is live on this call, evident either because analysts keep probing it or because management itself names it as a concern others hold — AND does management push back on that worry by pointing to CURRENT, ALREADY-OBSERVED evidence from the business showing that the feared outcome is, so far, NOT materializing? Answer YES when BOTH halves come through in the transcript as one coherent dynamic, in whatever form fits the business: (1) A NAMED, COMPANY-SPECIFIC FEAR THAT IS LIVE NOW. The worry is concrete and attached to this company — for example: that demand will fall off after an unusually strong stretch; that a major customer, contract, or partner will shrink, leave, or not renew; that a competitor, new technology, or cheaper alternative will take the company's business; that a key product, franchise, or pricing level is about to erode; that recent growth is a one-time bulge that will reverse; or another identifiable adverse outcome the market has been bracing for. The fear must be visible on the call itself — analysts returning to it in their questions, or management acknowledging in its own words that this is what people are worried about — not merely a generic risk factor or ordinary caution. (2) MANAGEMENT ANSWERS WITH OBSERVED BEHAVIOR, NOT REASSURANCE. Management responds by citing things that have ALREADY HAPPENED or are happening now — customers renewing, reordering, or expanding when they were expected to leave; demand holding or growing through the period when a drop-off was predicted; the threatened product, customer, or pricing actually performing in the recent period; competitive losses that have not shown up in real accounts; the feared cliff period arriving and being cleared — described with enough concrete substance (who, what, how much, or compared to when) that the rebuttal rests on evidence from the business rather than on confidence, promises, arguments about why the fear is illogical, or projections that the future will be fine. Answer NO if no specific company-attached worry is visible on the call — a routinely healthy company fielding ordinary questions is not this. Answer NO if the fear is visible but management's response is mainly reassurance, optimism, plans, or forecasts without already-observed evidence against it. Answer NO if the evidence shows the feared outcome IS materializing and management is excusing, minimizing, or promising to fix it. Answer NO if the worry is only broad macro or industry-wide gloom with nothing specific to this company's own business. Answer NO if management concedes the fear is valid and pivots to a different story instead of countering it. Answer NO if the counter-evidence is only a single vague assertion (such as 'demand remains strong') with no concrete grounding in what has actually occurred. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AVTR Avantor, Inc. Q2 2024 2024-07-26 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
MNKD MannKind Corporation Q4 2023 2024-02-27 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
TYGO Tigo Energy, Inc. Q4 2023 2024-02-14 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
BBVA Banco Bilbao Vizcaya Argentaria, S.A. Q4 2023 2024-01-30 B+
TBLA Taboola.com Ltd. Q3 2023 2023-11-08 B+
GMED Globus Medical, Inc. Q3 2023 2023-11-07 B
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
LNTH Lantheus Holdings, Inc. Q2 2023 2023-08-03 C+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
REYN Reynolds Consumer Products Inc. Q1 2023 2023-05-10 C
DOCN DigitalOcean Holdings, Inc. Q1 2023 2023-05-09 C+
ULCC Frontier Group Holdings, Inc. Q1 2023 2023-05-07 C+
AKR Acadia Realty Trust Q4 2022 2023-05-06 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
EPR EPR Properties Q1 2023 2023-04-27 C+
MEDP Medpace Holdings, Inc. Q1 2023 2023-04-25 B+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
POOL Pool Corporation Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
A Agilent Technologies, Inc. Q4 2022 2022-11-21 B+
PCTY Paylocity Holding Corporation Q1 2023 2022-11-05 A
TT Trane Technologies plc Q3 2022 2022-11-02 A
APOG Apogee Enterprises, Inc. Q2 2023 2022-09-20 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ZBRA Zebra Technologies Corporation Q2 2022 2022-08-02 C+
LIN Linde plc Q2 2022 2022-07-28 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
DCGO DocGo Inc. Q1 2022 2022-05-14 C
ZVIA Zevia PBC Q1 2022 2022-05-12 B
EGHT 8x8, Inc. Q4 2022 2022-05-10 C+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
BSX Boston Scientific Corporation Q1 2022 2022-04-27 B
CCK Crown Holdings, Inc. Q1 2022 2022-04-26 C+
FR First Industrial Realty Trust, Inc. Q1 2022 2022-04-21 A
SDIG Stronghold Digital Mining, Inc. Q3 2021 2021-11-30 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
HSY The Hershey Company Q3 2021 2021-10-28 C
PEP PepsiCo, Inc. Q3 2021 2021-10-05 B
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
PTVE Pactiv Evergreen Inc. Q2 2021 2021-08-08 C+
SPG Simon Property Group, Inc. Q2 2021 2021-08-02 B
GLW Corning Incorporated Q2 2021 2021-07-27 B+
DOV Dover Corporation Q2 2021 2021-07-20 B+
VLRS Controladora Vuela Compañía de Aviación, Q2 2021 2021-07-16 B+
MAR Marriott International, Inc. Q2 2018 2018-08-07 B
VALE Vale S.A. Q2 2018 2018-07-26 B
FICO Fair Isaac Corporation Q3 2018 2018-07-26 C+
ORAN Orange SA Q2 2018 2018-07-26 B
KIM Kimco Realty Corporation Q2 2018 2018-07-26 B+
TRUE TrueCar, Inc. Q1 2018 2018-05-08 C
TGNA TEGNA Inc. Q1 2018 2018-05-08 B+
CVS CVS Health Corporation Q1 2018 2018-05-02 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
MIDD The Middleby Corporation Q4 2017 2018-02-28 C
SBUX Starbucks Corporation Q1 2018 2018-01-26 C
AVT Avnet, Inc. Q2 2018 2018-01-25 B
GURE Gulf Resources, Inc. Q3 2017 2017-11-14 F
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
PII Polaris Inc. Q3 2017 2017-10-24 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BCRX BioCryst Pharmaceuticals, Inc. Q1 2017 2017-05-07 B
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
CGNT Cognyte Software Ltd. Q4 2016 2017-03-09 D
BDC Belden Inc. Q4 2016 2017-02-02 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
LPSN LivePerson, Inc. Q1 2016 2016-05-04 B
UVE Universal Insurance Holdings, Inc. Q1 2016 2016-05-03 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
VRTS Virtus Investment Partners, Inc. Q1 2016 2016-04-29 D
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
BX Blackstone Inc. Q1 2016 2016-04-21 B
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.

More from the question bank

Doors opening at the company's own gatesReporting the counterparty's growth as its oSecond proving already underwayNew normal declared and staffedBigger than they can carry aloneDemand arrived first, the company is growingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.